This page is part of the Data Exchange Profiles for 2022 CDC Clinical Practice Guideline for Prescribing Opioids (v1.0.0-ballot: STU 1 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. No current official version has been published yet. For a full list of available versions, see the Directory of published versions
Page standards status: Informative |
CodeSystem | Description |
---|
ValueSet | Description |
---|---|
Amphetamine-class drugs and metabolite urine tests | Urine tests, both quantitative and qualitative, including confirmatory, that detect Amphetamine-class drugs and metabolites |
Amphetamine class medications | Amphetamine class medications based upon the mapping of SNOMED CT drug class to ingredient then linked to RXNorm |
Barbiturate Medications | All Barbiturate medications |
Barbiturate urine drug screening tests | Presumed general urine tests for barbiturates that are not specific to a particular substance. |
Benzodiazepine medications | All benzodiazepine clinical drugs |
Benzodiazepine urine drug screening tests | Presumed general urine tests for benzodiazepines that are not specific to a particular substance. |
Buprenorphine Medications | All Buprenorphine medications |
Buprenorphine urine drug screening tests | Presumed general urine tests for buprenorphine. |
Cannabinoid class urine drug screening | Cannabinoid, including synthetic and THC, urine tests |
CDC malignant cancer conditions | All neoplastic and malignant conditions, including pain due to neoplasm. |
CNS depressant medications | Medications considered to have an ingredient considered to be a CNS depressant, some of which may be mild. Removed from this set are cough medications and bowl transit modifiers. |
Cocaine urine drug screening tests | Urine tests for cocaine and cocaine metabolites |
Conditions likely terminal for opioid prescribing | Conditions that generally are thought to have terminal prognosis |
Extended release opioid with ambulatory misuse potential | All opioid clinical drugs except those restricted to surgical use only, and that are in an extended release dose form code |
Fentanyl-type medications | Fentanyl and similar medications (sufentanil, alfentanil, remifentanil) |
Fentanyl-type urine drug screening tests | Urine tests for fentanyl-type drugs and metabolites |
General opiate urine drug screening tests | Presumed general urine tests for naturally occurring opioids (i.e. opiates) that are not specific to a particular substance based upon the inclusion of the word 'opiates' in the long name. |
Heroin urine drug screening tests | Presumed general urine tests for heroin and metabolites. |
Methadone medications | Medication codes representing methadone medications |
Methadone urine drug screening tests | Urine tests to identify methadone and metabolites |
Naloxone medications | All naloxone medications |
Non-synthetic opioid medications | Medications derived from the opium plant that are not synthetically created . All metabolize to morphine. |
Opioid analgesics with ambulatory misuse potential | All opioid clinical drugs except cough medications, antispasmodics, or those restricted to surgical use only as identified by those using an injectable form. |
Opioid misuse assessment procedure | Procedure to assess the risk of opioid abuse occurring by a patient |
Oxycodone Medications | All Oxycodone medications |
Oxycodone urine drug screening tests | Presumed general urine tests for oxycodone. |
Pain management procedure | Procedure for subacute or chronic pain control management |
Pain treatment plan | A Pain medicine Plan of care note |
PDMP data reviewed finding | Finding indicating that the Prescription Drug Monitoring Program (PDMP) data was reviewed |
PDMP review procedure | Procedure for Prescription Drug Monitoring Program (PDMP) review |
Phencyclidine urine drug screening tests | Urine tests for phencyclidine |
Sickle-cell diseases | Sickle-cell disorders that cause painful crisis |